YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer

<div>The immune landscape of EGFR-mutant NSCLC. (a) PC analysis in EGFR-mutant NSCLC patients revealed an obvious clustering between the YAP1_High and YAP1_Low groups. (b) GO and KEGG enrichment analysis of EGFR-mutant NSCLC in the YAP1_High group.</div>

Canadian Respiratory Journal

fig5

Figure 5

Figure 5: YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer 